Skip to main content
Publications
Ogilvie RP, Layton JB , Lloyd PC, Jiao Y, Djibo DA, Wong HL, Gruber JF, Parambi R, Deng J, Miller M, Song J, Weatherby LB, Peetluk L, Lo A, Matuska K, Wernecke M, Bui CL , Clarke TC, Cho S, Bell EJ, Yang G, Amend KL, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Anthony MS , Seeger JD, Shoaibi A. Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study . BMC Pediatr. 2024 Apr 26;24(1):276. doi: 10.1186/s12887-024-04756-5
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R , Zhou X , Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era . Br J Haematol. 2016 Mar;172(5):724-34. doi: 10.1111/bjh.13895
Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X , Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States . Br J Haematol. 2015 Jul;170(1):85-95. doi: 10.1111/bjh.13399
Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X , Copley-Merriman C , Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy . Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375